mRNA-1273.211
PreclinicalRNA therapy
ModernamRNA-1273.211 is one of 21 biologic programs targeting COVID-19. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Benadryl
PParkedale
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Moderna COVID-19 Vaccine
ModernaPreclinical
Hydroxychloroquine Pill
UUniversity of Calgary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-191 trial
SARS-CoV-21 trial
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04889209·867 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mRNA-1273.211. EMBL-EBI & Wellcome Sanger Institute.
- [4]